Printer Friendly
The Free Library
19,604,530 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

DiaSys Corporation Reports 57% Increase in First Quarter Year over Year Revenues.


WATERBURY, Conn. -- DiaSys Corporation (AMEX AMEX

See: American Stock Exchange
:DYX DYX Dyslexia ) a global healthcare products company, today reported sales results for the first quarter ended September 30, 2004. Revenue was $568,456 in the first quarter of 2004, an increase of 57% over revenue of $361,388 in the first quarter of 2003.

"We have made excellent progress on all our stated goals during the first quarter and will continue to see accelerating sales growth" said Morris Silverman, Chairman. "We are generating increasing sales as a result of our new sales team. We remain very committed to reaching our long term goals for the Company."

DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease Infectious disease

A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions.
 test kits to healthcare and veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary Wholly Owned Subsidiary

A subsidiary whose parent company owns 100% of its common stock.

Notes:
In other words, the parent company owns the company outright and there are no minority owners.
 based in Wokingham England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation.

This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
 provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on form 10-KSB and other SEC filings for a complete description of, and discussions about, the company.
COPYRIGHT 2004 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Oct 6, 2004
Words:267
Previous Article:Newt Gingrich and Siemens Medical CEO Erich Reinhardt Share Insight on the Future of Healthcare; Results of Opinion Leader Survey Will Be Revealed.
Next Article:PwC Studies Show Outsourcing Saves 35 Percent on Payroll and 50 Percent on HRIS When Compared to in-House System Costs; Outsourcing Provides Cost...
Topics:



Related Articles
DiaSys Corporation Announces Settlement of Arbitration with Former Co-Founder Chief Executive Officer.
DiaSys Corporation Announces Fourth Quarter Sales Increase of 19% over Third Quarter.
DiaSys Corporation Announces the Introduction of new FDA and CE Marked ELISA Product Line.
DiaSys Enters Costa Rican Market Through Distribution Agreement with Largest Clinical Diagnostics Distributor in the Country; Company Enters...
DiaSys Continues International Expansion Through Entrance Into Australian Market; Company Selects Laboratory Diagnostics To Distribute Diagnostics...
DiaSys Enters into Distribution Agreement with Largest Clinical Distributor in Chile; Company Continues Rapid Expansion in Latin America Through...
DiaSys Corporation Announces First Quarter Financial Information.
DiaSys Corporation Announces $11.75 Million Order in Mexico for the Company's Parasitology Products.
DiaSys Corporation Announces $2.7 Million Award in Venezuela for the Company's Parasitology Products.
DiaSys Corporation Announces $1.46 Million Order In Latin America.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles